Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer

類似資料

• A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer
  著者:: Yoo, Changhoon, 等
  出版事項: (2015)
• The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine
  著者:: Javan-Noughabi, Javad, 等
  出版事項: (2018)
• Adriamycin-Cyclophosphamide (AC) followed by Paclitaxel-Cisplatin (PC). A highly active neoadjuvant regimen in locally advanced breast cancer
  著者:: Mendoza-Posada, Daniel, 等
  出版事項: (2007)
• The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients
  著者:: Wu, Xian, 等
  出版事項: (2021)
• Value of volume-based metabolic parameters for predicting survival in breast cancer patients treated with neoadjuvant chemotherapy
  著者:: Kim, Tae Hee, 等
  出版事項: (2016)